AM-Pharma Successfully Completes Patient Enrollment
AM-Pharma B.V. has reached a significant milestone in its clinical journey by successfully completing the enrollment of patients for its Phase 2 trial. This study focuses on ilofotase alfa, a promising therapeutic candidate aimed at preventing cardiac surgery-associated renal damage (CSA-RD). CSA-RD is a prevalent complication that may affect up to 40% of patients undergoing cardiac surgery, causing considerable health repercussions.
Understanding Cardiac Surgery-Associated Renal Damage
CSA-RD is a serious concern for patients as it can lead to acute kidney injury (AKI). After cardiac surgery, the risk of kidney complications increases significantly, leading not only to short-term health challenges but also to prolonged hospital stays, higher chances of requiring renal replacement therapy, and increased mortality risk. Without effective pharmacological options currently available, addressing this urgent medical need has never been more critical.
Insights from the Study's Key Investigator
Dr. Peter Pickkers, leading the Phase 2 study and serving as a Professor of Experimental Intensive Care Medicine, highlighted the need for innovative treatments. Given the absence of effective therapies for CSA-RD, this trial seeks to validate the protective effects of ilofotase alfa seen in previous research. The aspirations are to usher in a new era of treatment options for patients vulnerable to renal injury post-surgery.
Details of the Phase 2 Clinical Trial
This clinical trial, registered as NCT06168799, is a multicenter, international effort involving 244 patients classified as high-risk for renal damage. Each participant received two intravenous doses of ilofotase alfa—one prior to surgery and another following the procedure. The ongoing assessment includes monitoring the participants for 60 days to evaluate the treatment's efficacy, safety, and pharmacokinetics. The primary endpoint focuses on measuring serum creatinine ratio (sCrR), which serves as a critical indicator of kidney function changes correlating with Major Adverse Kidney Events (MAKE60).
Topline Data and Future Prospects
AM-Pharma anticipates topline data to be available in early 2026. This data will include critical insights on MAKE60, potentially serving as a primary endpoint in a future Phase 3 trial for ilofotase alfa. Such developments could have substantial implications for patients in need and pave the way for groundbreaking treatments in renal protection.
The Mechanism of Ilofotase Alfa
Ilofotase alfa is a recombinant alkaline phosphatase designed to address inflammatory responses and kidney injury. Its therapeutic action involves dephosphorylating various damaging substances associated with acute renal inflammation. This dual-action mechanism—removal of pro-inflammatory ATP and promotion of adenosine production—helps protect the kidney tissue effectively during injury.
Broader Applications of Ilofotase Alfa
AM-Pharma is exploring ilofotase alfa for two therapeutic applications: an intravenous formulation for patients with AKI and a concentrated subcutaneous formulation intended for long-term treatment of hypophosphatasia (HPP). Recent studies underline the dual benefits of the subcutaneous formulation, demonstrating positive outcomes not only related to kidney health but also extending to muscle metabolism and overall vitality in patients.
About AM-Pharma
AM-Pharma is committed to developing innovative medicines for patients experiencing severe health challenges. Their work involves pioneering therapies for AKI, and they have garnered FDA fast-track status for ilofotase alfa. With numerous clinical trials involving approximately 1,000 subjects, AM-Pharma is attentive to the needs of patients and continues to push the boundaries in renal health and disease management.
Frequently Asked Questions
What is ilofotase alfa?
Ilofotase alfa is a recombinant alkaline phosphatase designed to prevent renal damage, particularly during cardiac surgery.
What is CSA-RD?
Cardiac surgery-associated renal damage (CSA-RD) is kidney injury that occurs in patients following open-heart surgery.
What does the clinical trial involve?
The trial involves administering ilofotase alfa to high-risk patients undergoing open-heart surgery and monitoring their kidney function post-surgery.
When can we expect results from the trial?
Topline results from the trial are expected to be released in early 2026.
Why is this research important?
This research addresses a significant unmet medical need, as there are currently no effective therapies to prevent renal damage associated with cardiac surgery.
